Chargement en cours...
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
In the last three years, five novel treatments have been shown to improve survival in metastatic castration-resistant prostate cancer (CRPC). These novel treatments have distinct mechanisms of action: tubulin-binding chemotherapy (cabazitaxel); immunotherapy (sipuleucel-T); CYP-17 inhibition (abirat...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publications
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3891292/ https://ncbi.nlm.nih.gov/pubmed/24489604 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287213509677 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|